Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment

Now Enrolling Patients with Myelofibrosis

Phase III studies investigating INCB018424—
an oral JAK1/JAK2 inhibitor

In this Web site you will find information on 2 clinical trials, COMFORT-I and COMFORT-II, currently evaluating the investigational agent INCB018424 for the treatment of myelofibrosis. Additional useful resources include trial recruitment information and brief overviews of selected topics such as myelofibrosis, the JAK pathway, and preliminary clinical results.

This information is intended for use by healthcare providers only.

..........................................................................................................................................................................................................................................................................................................................

This is an international Web site for the COMFORT-I and COMFORT-II trials. The information on this site is not country-specific and may contain trial information that is different from where you practice. INCB018424 is investigational. Efficacy and safety have not been established. There is no guarantee that this compound will become commercially available.

Now Enrolling Patients with Myelofibrosis

Phase III studies investigating INCB018424—an oral JAK1/JAK2 inhibitor

Phase III studies investigating INCB018424—
an oral JAK1/JAK2 inhibitor